Insulin Pump Therapy
Insulin Pump Therapy - Related Videos
05:52
Insulin Injection and Hemolymph Extraction to Measure Insulin Sensitivity in Adult Drosophila melanogaster
0 Views •
Cited by 16 •
2011
Conserved insulin signaling pathways found in the fruit fly Drosophila melanogaster make this organism a potential tool for modeling metabolic disorders including type II diabetes. To this end, it is critical to establish physiological assays to effectively measure systemic insulin action in peripheral glucose disposal in the adult fly.
01:30
ATP Driven Pumps III: V-type Pumps
0 Views •
2023
V-type pumps are ATP-driven pumps found in the vacuolar membranes of plants, yeast, endosomal and lysosomal membranes of animal cells, plasma membranes of a few specialized eukaryotic cells, and some prokaryotes. They are also known as the V1Vo-ATPase, that couple ATP hydrolysis to transport protons against a concentration gradient. The peripheral or cytosolic V1 domain with eight subunits is involved in ATP hydrolysis. The integral or transmembrane V0 domain containing at least five subunits...
01:34
ATP Driven Pumps II: P-type Pumps
0 Views •
2023
The P-type pumps are a large family of integral membrane transporter ATPases. They are divided into five major types based on substrate specificity, from I to V. A typical P-type pump has three cytosolic domains: nucleotide-binding (N), phosphorylation (P), and activator (A) domains. These domains are connected to the membrane-spanning helices by short amino acid segments. ATP hydrolysis and covalent phosphoenzyme intermediate formation are crucial parts of the catalytic cycle. At the highly...
12:08
Improving IV Insulin Administration in a Community Hospital
0 Views •
Cited by 7 •
2012
When compared to the previous paper protocol, implementation of a computerized glucose management system results in a substantial increase in blood glucose concentration measurements within the target range. Using a computerized glucose management system to monitor blood glucose levels, decreases in severe hypoglycemia (<40 mg/dL), clinical hypoglycemia (<70 mg/dL), and hyperglycemia (>180 mg/dL) also can be observed.
14:39
A Quantitative Assay for Insulin-expressing Colony-forming Progenitors
0 Views •
Cited by 11 •
2011
A three-dimensional clonogenic assay that allows pancreatic-like progenitors to differentiate into insulin-expressing colonies is described. This method takes advantage of semi-solid media containing methylcellulose, Matrigel and growth factors, in which single progenitors proliferate and differentiate in vitro, permitting quantification of the number of functional progenitors in a population.
FAQs
Basal delivery provides a programmed, continuous background supply of rapid-acting insulin, while bolus doses address short-term increases in glucose associated with meals or elevated readings. Separating these functions allows insulin delivery to reflect changing needs throughout the day. The approach therefore supports more flexible dosing than relying only on scheduled multiple daily injections.
Insulin pump therapy uses rapid-acting insulin so the device can provide ongoing basal delivery and additional boluses through the same infusion system. This arrangement links background replacement with meal-related or corrective dosing. Because the system depends on programmed delivery and user-directed boluses, dosing can be individualized according to the person’s glucose-management needs.
Continuous glucose monitoring supplies changing glucose information that can guide insulin delivery decisions. In some integrated systems, the pump can adjust delivery in response to those glucose levels rather than relying solely on fixed programming. This pairing may help align insulin administration more closely with current glucose patterns and strengthens the individualized nature of diabetes care.
The process begins with programmed basal insulin delivery through an infusion set. The user then delivers a bolus dose when eating or when blood glucose is elevated and a correction is needed. When continuous glucose monitoring is available, its readings can inform adjustments or dosing decisions, depending on the capabilities of the paired system.
People with type 1 diabetes commonly use this approach when they require intensive glucose management. It may also be considered in selected cases of type 2 diabetes, although suitability is individualized. The central clinical consideration is whether flexible basal and bolus delivery can support the person’s insulin needs and overall diabetes-care plan.
Rather than depending on repeated scheduled injections alone, pump therapy delivers a programmed basal rate and allows additional boluses for meals or elevated glucose. This structure offers greater dosing flexibility, particularly when insulin needs vary. Its value lies in supporting individualized glucose management, while the appropriate choice depends on the person’s clinical situation and care goals.